Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

ABSTRACT:

Importance

Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).

Objectives

To evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR.

Design, setting, and patients

This prespecified subgroup comparative effectiveness analysis followed the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated vs Standard DAPT Regimen (MASTER DAPT) trial, a multicenter, randomized, open-label clinical trial conducted at 140 sites in 30 countries and performed from February 28, 2017, to December 5, 2019. A total of 4579 patients

SUBMITTER: Landi A 

PROVIDER: S-EPMC10666042 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature